Thymalfasin (Thymosin alpha 1, Ta1)
Sponsors
SciClone Pharmaceuticals, The Methodist Hospital Research Institute, Beijing Friendship Hospital, Shanghai Zhongshan Hospital
Conditions
COVID-19 VaccineEGFR Mutation Positive Non Small Cell Lung CancerImmune Response to Covid 19 VaccinationImmunosuppressionMCRCNon-Small Cell Lung CancerSepsisVaccine Response
Phase 1
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
NCT02906163
Start: 2016-10-31End: 2020-01-31Target: 188Updated: 2016-09-19
Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
RecruitingNCT06821100
Start: 2024-12-02End: 2026-12-01Target: 75Updated: 2026-07-16
Phase 2
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
NCT02906150
Start: 2016-09-30End: 2019-07-31Target: 140Updated: 2016-09-19
Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer
RecruitingNCT06829355
Start: 2025-02-11End: 2027-12-31Target: 52Updated: 2025-02-17